Report: Drugmakers may have ducked $1.3B in Medicaid rebates

Without calling out any drug companies by name, the U.S. Dept. of Health and Human Services’ Office of Inspector General revealed this week that 10 potentially misclassified drugs may have resulted in $1.3 billion in lost rebates to Medicaid between 2012 and 2016.

The issue of ducking rebates came to the public’s attention earlier this year when Mylan (NSDQ:MYL) reached a $465 million settlement with the Dept. of Justice to resolve claims that the company misclassified its EpiPen auto-injectors as generic rather than branded to avoid paying a higher rebate.

Get the full story at our sister site, Drug Delivery Business News.

The post Report: Drugmakers may have ducked $1.3B in Medicaid rebates appeared first on MassDevice.

from MassDevice http://ift.tt/2p7temj